Unicorn Moderna joins lineup to list on Hong Kong's exchange; Processa licenses compound from Concert
→ Rumors are flying that biotech’s biggest unicorn, Moderna, which was recently valued at $7 billion, is planning a dual IPO listing on both the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
